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Introduction: Human mesenchymal stem cells (hMSCs) reside in a perivascular niche of the body, suggesting that
they interact closely with vascular endothelial cells (ECs) through cell-cell interaction or paracrine signaling to maintain
cell functions. Endothelin-1 (ET1) is a paracrine factor mainly secreted by ECs. We thus hypothesize that ECs can
regulate cellular activities of hMSCs and direct their stem cell fate.
Methods: We investigated whether co-cultured human aortic endothelial cells (HAECs) were able to regulate
expression of potency- and lineage-related markers in bone marrow-derived hMSCs. We further explored the
regulatory effects of ET1 on cell proliferation, expression of surface antigens and pluripotency-related markers,
and multilineage differentiation in hMSCs. Activation of the AKT signaling pathway in hMSCs was also analyzed to
identify its mechanistic role in the ET1-induced regulation.
Results: Co-cultured HAECs enhanced expression of mesenchymal lineage-related markers in hMSCs. Treatment
of ET receptor antagonist downregulated the increased expression of CBFA1 in hMSCs cultured with HAEC-conditioned
medium. hMSCs treated with ET1 showed cell proliferation and expression of surface antigens, CD73, CD90, and
CD105, comparable with those without ET1 treatment. ET1-treated hMSCs also expressed upregulated mRNA transcript
levels of OCT3/4, NANOG, CBFA1 and SOX9. When induced for lineage-specific differentiation, hMSCs pre-treated with
ET1 showed enhanced osteogenesis and chondrogenesis. However, adipogenic differentiation of hMSCs was not
affected by ET1 pretreatment. We further showed that the ET1-induced regulation was mediated by activation of
AKT signaling.
Conclusion: Our results demonstrate that ET1 secreted by HAECs can direct bone marrow-derived hMSCs for
osteo- and chondro-lineage differentiation through activation of the AKT signaling pathway, suggesting that ET1
plays a crucial role in regulation of hMSC activity. Our findings may help understand how hMSCs interact with
ECs in a perivascular niche.Introduction
Human mesenchymal stem cells (hMSCs) are multipotent
and capable of self-renewal [1-3]. They can be isolated
from various adult and fetal tissues [4-6], and can be
induced into osteo-, chondro-, or adipo-lineage cells
in vitro and in vivo [7]. With these features, hMSCs hold
great potential for regenerative medicine applications. To* Correspondence: li@ortho.wisc.edu
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voted to understanding mesenchymal stem cell (MSC) biol-
ogy and controlling MSC behavior.
While hMSCs regulated by physical or chemical sig-
nals have been studied in cell culture, the knowledge
about hMSC behavior in vivo, particularly interaction
with other cell types, remains largely unknown [8-10].
Recent studies have shown that properties of pericytes
are similar to those of MSCs [11-14]. Researchers have
also reported that hMSCs isolated from bone marrow
express CD146, a surface marker of pericytes [15,16].
These reports concordantly indicate that hMSCs reside
in a perivascular niche of the body. The anatomicalis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(ECs) also suggests that these two cell types interact with
each other likely through cell-cell interaction and/or para-
crine signaling. Indeed, Kaigler and colleagues havedemonstrated that ECs enhance osteogenic differentiation
of hMSCs through direct cell-cell contact [17]. Using EC-
conditioned medium for hMSC culture, Saleh and col-
leagues have shown that the paracrine signaling molecules
secreted by ECs increase proliferation and osteogenic dif-
ferentiation of hMSCs [18]. Another study by Saleh and
colleagues has reported that ECs increase osteogenesis but
decrease adipogenesis of hMSCs in a three-dimensional
spheroid co-culture system [19]. Together these findings
demonstrate that ECs are able to regulate hMSC activities.
However, the underlying mechanism has not been fully
identified.
Endothelin-1 (ET1) is a secretory factor produced by ECs
[20,21]. Several research reports have demonstrated that
ET1 is involved in the regulation of osteogenic differenti-
ation, suggesting that ET1 may play a pivotal role in regula-
tion of MSC activities. For example, von Schroeder and
colleagues have shown that ET1 promotes osteoprogenitor
proliferation and differentiation in fetal calvarial cell culture
[22]. Clines and colleagues have demonstrated that ET
signaling is an important regulator of postnatal trabecular
bone formation [23,24]. In addition, a study by Salama
and colleagues has shown that ET1 enhances proliferation
and migration of hMSCs and increases expression of
alpha smooth muscle actin in hMSCs [25]. These studies
collectively suggest that ECs may secrete ET1 to regulate
hMSC activities.
ET1 binds to endothelin receptor type A or B on the cell
surface to activate downstream signaling molecules of
several pathways, including mitogen activated-protein
kinase [26,27], Ca2+/calmodulin-dependent protein kin-
ase [28], protein kinase C [29,30], and phosphatidylinositol
3-kinase/AKT [31,32]. It is known that these signaling
molecules play a role in regulation of MSC behavior. For
example, our group has previously demonstrated that
AKT signaling is involved in the regulation of hMSC
senescence in hypoxic culture [33]. Inhibition of AKT
signaling results in increased hMSC senescence and de-
creased expression of pluripotency-related markers. Other
groups have also reported that activation of AKT signaling
suppresses cell senescence, maintains stem cell properties,
and regulates MSC differentiation [34-37]. Therefore, it is
worthwhile to study whether ET1 regulates MSC activities
through activation of AKT signaling.
In this study, we hypothesized that ECs secrete ET1 to
regulate hMSC activities, and the regulatory effects of
ET1 on hMSCs are mediated by the AKT signaling path-
way. To test our hypothesis, bone marrow-derived hMSCs
were co-cultured with human aortic endothelial cells
(HAECs) or treated with recombinant ET1 in culture, and
then analyzed for cell proliferation, expression of surface
antigens, and multilineage differentiation. Activation of
AKT signaling by ET1 in hMSCs was also analyzed to
determine the underlying mechanism.
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Human mesenchymal stem cell isolation and cell culture
Ethical approval of human tissue procurement for this
study was granted by the Institutional Review Board at
the University of Wisconsin-Madison. Bone marrow-
derived hMSCs were harvested from femoral heads and
necks of one male and two female patients undergoing
total hip arthroplasty. The cells from each donor were
individually cultured and assayed in this study. Approved
by the Institutional Review Board, informed consent from
patients was waived in accordance with federal regulations
of human tissue obtained as surgical waste for biomedical
research. hMSCs were isolated following a previously
described protocol [38]. Briefly, after harvested from
the interior compartment of femoral head and neck,
bone marrow was mixed with Dulbecco’s modified
Eagle medium (DMEM; Gibco, Carlsbad, CA, USA). A
syringe with an 18-gauge needle was used to filter out
bone debris from the bone marrow/DMEM mixture. The
collected medium was then centrifuged at 1,000 rpm for 5
minutes. After removing the supernatant, the resulting cell
pellet was reconstituted using 25 ml Hank's Balanced
Salt Solution (Invitrogen, Carlsbad, CA, USA), and then
slowly added into a 50 ml conical tube containing 20
ml Ficoll solution (GE Health, Pittsburgh, PA, USA). After
centrifugation at 500 g for 30 minutes, mononuclear cells
were collected and plated in cell culture flasks with cul-
ture medium composed of low-glucose DMEM, 10% fetal
bovine serum (FBS; Atlanta Biologicals, Atlanta, GA,
USA) and antibiotics. The cells were maintained in an in-
cubator at 37°C in a humidified 5% CO2 atmosphere.
When reaching 70 to 80% density confluence, the cells
were trypsinized using 0.05% trypsin/EDTA (Gibco) and
re-plated at a seeding density of 1,000 cells/cm2. Culture
medium was replaced every 3 days. Cells between pas-
sages 2 and 4 were used in this study.
Culture of human embryonic stem cell-derived mesenchymal
stem cells
Human embryonic stem cell-derived (hESC)-MSCs were
obtained from Dr. Igor Slukvin through collaboration.
The cells were previously derived from H1 hESCs and
thoroughly characterized [39]. The experiments involving
hESC-MSCs were approved by the Institutional Biosafety
Committee at the University of Wisconsin-Madison. After
thawing, hESC-MSCs were plated in tissue culture plates
coated with 5 μg/ml human fibronectin (Invitrogen) and
10 μg/ml human collagen type 1 (Stem Cell Technologies,
Vancouver, Canada), and cultured in medium composed
of 50% StemLine II hematopoietic stem cell serum-free
medium (Sigma-Aldrich, St Louis, MO, USA), 50%
Human Endothelial serum-free medium (Gibco), 100
μM monothioglycerol (Sigma-Aldrich), 1:100 dilution
Glutamax (Gibco), 1:2,000 dilution ExCyte supplement(EMD Millipore, Billerica, MA, USA), 10 ng/ml fibroblast
growth factor-2 (Peprotech, Rocky Hill, NJ, USA), and an-
tibiotics. The cells were maintained in an incubator at 37°
C in a humidified 5% CO2 atmosphere. When reaching 70
to 80% density confluence, the cells were collected using
Accutase (Life Technologies, Carlsbad, CA, USA) and
re-plated at a seeding density of 1,000 cells/cm2.
Culture medium was replaced every 3 days.Co-culture of human mesenchymal stem cells and human
aortic endothelial cells
HAECs derived from a female donor were obtained from
Lonza (Lonza, Allendale, NJ, USA). After thawing, the
cells were plated in tissue culture flasks with culture
medium composed of Endothelial Basal Medium-2 (Lonza),
10% FBS and antibiotics, and maintained in an incubator at
37°C in a humidified 5% CO2 atmosphere. Cells between
passages 5 and 7 were used for all experiments. When
culture medium was replaced every 2 days, HAEC-
conditioned medium was collected and stored in a −20°C
freezer for later use.
To set up co-culture of hMSCs and HAECs in Trans-
well System (BD Biosciences, San Diego, CA, USA) as il-
lustrated in Figure 1A, hMSCs were plated at the bottom
of 6-well plates at a seeding density of 1,000 cells/cm2 and
HAECs were plated in transwell inserts at a seeding dens-
ity of 2,000 cells/cm2. The co-culture with medium com-
posed of 50% hMSC culture medium and 50% HAEC
culture medium was maintained at 37°C in a humidified
5% CO2 atmosphere.
To study the role of ET1 in regulation of hMSC activ-
ities, HAEC-conditioned medium was prepared by filter-
ing the medium collected from HAEC culture using a
0.22 μm syringe filter (EMD Millipore) and mixing it with
the same volume of fresh HAEC culture medium, and
then using it to treat hMSCs with or without 1 or 10 μM
bosentan (AvaChem Scientific, San Antonio, TX, USA),
a non-selective endothelin receptor antagonist. hMSCs
maintained with fresh HAEC culture medium served as
a control.Cell proliferation analysis
hMSCs co-cultured with HAECs or treated with 0.01 or
0.1 μM ET1 in culture were harvested and digested over-
night using Proteinase K (Sigma-Aldrich) to extract
DNA. The total amount of double-stranded DNA was
analyzed to determine cell proliferation using the Pico-
Green assay (Invitrogen) following the manufacturer’s
instructions.
Long-term growth of hMSCs in culture with or without
0.1 μM ET1 was determined by measuring accumulated
population doublings (PDs). Cell number was calculated at
each passage by counting the cells using a hemocytometer.
Figure 1 Activities of human mesenchymal stem cells (hMSCs) regulated by co-cultured human aortic endothelial cells (HAECs) or HAEC-conditioned
medium. (A) Illustration of hMSC/HAEC Transwell co-culture setup. hMSCs were seeded at the bottom of wells while HAECs were seeded in Transwell
inserts. (B) Micrographs of control hMSCs or hMSCs co-cultured with HAECs. Scale bar: 200 μm. (C). Proliferation of hMSCs co-cultured with or without
HAECs was analyzed by quantifying total DNA content. (D) Relative mRNA expression levels of potency- and lineage-related markers in control
hMSCs or hMSCs co-cultured with HAECs for 3 days were analyzed by quantitative RT-PCR. (E) Concentrations of soluble endothelin-1 (ET1) in
hMSC- or HAEC-conditioned medium (CM) were quantified using enzyme-linked immunosorbent assay (left). Relative mRNA expression levels
of ET1 in hMSCs or HAECs were determined by quantitative RT-PCR (right). (F) Relative mRNA expression levels of potency- and lineage-related
markers in hMSCs treated without HAEC-conditioned medium (CM-), or with HAEC-conditioned medium (CM+) added with or without
bosentan for 3 days were analyzed by quantitative RT-PCR. *P < 0.05; n = 3. ND, not detectable.
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PD = log2 (C1/C0), where C0 = the number of cells initially
seeded and C1 = the number of cells being passaged.Total RNA extraction and quantitative reverse
transcription polymerase chain reaction
Total RNA was extracted from cells using the Nucleo
Spin RNA II kit (Clontech, Mountain View, CA, USA)
following the manufacturer’s instructions. Complemen-
tary DNA was transcribed from 500 ng RNA using the
High-Capacity cDNA Reverse Transcription kit (Applied
Biosystems, Carlsbad, CA, USA). Quantitative RT-PCR
(qRT-PCR) was performed using the iQ SYBR Green
Premix (BioRad, Hercules, CA, USA) with primers detect-
ing octamer binding transcription factor 3/4 (OCT3/4),
NANOG, core-binding factor subunit alpha-1 (CBFA1),
sex determining region Y-box 9 (SOX9), peroxisome
proliferator-activated receptor gamma 2 (PPARG2), ET1,
alkaline phosphatase (ALP), osteocalcin (OC), aggrecan
(AGN), collagen type 2 (COL2), lipoprotein lipase (LPL)
and ubiquitin C (UBC). OCT3/4 and NANOG are recog-
nized pluripotent transcription factors in ESCs. As it has
been reported that low levels of these factors is a featureof early passage hMSCs [40,41], the mRNA expression of
OCT3/4 and NANOG was analyzed to assess the undiffer-
entiated state of hMSCs, and that of the other genes was
analyzed to determine tissue lineage-specific differenti-
ation [33]. The primer sequences are listed in Table 1. The
expression level of each mRNA transcript was determined
by referencing to that of UBC using the 2-ΔCt method.
Quantification of endothelin-1 levels in culture
Conditioned medium was collected from hMSC or HAEC
culture during medium changing and the collected
medium from two lots of medium changing was com-
bined for analysis. The concentration of soluble ET1 in
hMSC- or HAEC-conditioned medium was determined
using the ET1 enzyme-linked immunosorbent assay kit
(R&D Systems, Minneapolis, MN, USA) following the
manufacturer’s instructions.
Flow cytometric analysis of mesenchymal stem cell
surface antigens
hMSCs treated with or without 0.1 μM ET1 were trypsi-
nized and washed twice using ice-cold phosphate-buffered
saline containing 0.1% sodium azide and 1% bovine serum






Primer sequences (5′ to 3′)
OCT3/4 NM_002701.4 F: TGGAGAAGGAGAAGCTGGAGCAAAA
R: GGCAGATGGTCGTTTGGCTGAATA
NANOG NM_021865.2 F: GCTGAGATGCCTCACACGGAG
R: TCTGTTTCTTGACCGGGACCTTGTC
CBFA1 NM_004843.3 F: GGTTCCAGCAGGTAGCTGAG
R: AGACACCAAACTCCACAGCC
SOX9 NM_000346.3 F: TAAAGGCAACTCGTACCCAA
R: ATTCTCCATCATCCTCCACG
PPARG2 NM_138711.3 F: ATGACAGCGACTTGGCAATA
R: GGCTTGTAGCAGGTTGTCTT
ET1 NM_001168319.1 F: AAGGCAACAGACCGTGAAAAT
R: CGACCTGGTTTGTCTTAGGTG
ALP NM_000478.3 F: CAAAGGCTTCTTCTTGCTGG
R: GGTCAGAGTGTCTTCCGAGG
OC NM_199173.3 F: GACTGTGACGAGTTGGCTGA
R: GGAAGAGGAAAGAAGGGTGC
AGN NM_013227.2 F: CACGATGCCTTTCACCACGAC
R: TGCGGGTCAACAGTGCCTATC
COL2 NM_001844.4 F: CCTCTGCGACGACATAATCT
R: CTCCTTTCTGTCCCTTTGGT
LPL NM_000237.2 F: AGGAGCATTACCCAGTGTCC
R: GGCTGTATCCCAAGAGATGGA
UBC NM_021009.4 F: TGAAGACACTCACTGGCAAGACCA
R: CAGCTGCTTTCCGGCAAAGATCAA
Forward and reverse primers are indicated as “F” and “R”, respectively.
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with the antibodies against cell surface markers CD73,
CD90 and CD105 (BD Biosciences) for 30 minutes at 4°C.
After washing with the buffer three times to remove un-
bound antibodies, the cells were fixed with 1% paraformal-
dehyde solution, and then analyzed by flow cytometry
(BD Biosciences). Data were analyzed using the FlowJo
software (TreeStar, Ashland, OR, USA).Assessment of multilineage differentiation of human
mesenchymal stem cells
To investigate whether ET1 can prime the capability of
undifferentiated hMSCs for multilineage differentiation,
hMSCs were maintained in culture with or without
0.1 μM ET1 for two passages and then induced for osteo-,
adipo- and chondrogenesis without ET1 for 21 days. The
cells were trypsinized and replated in tissue culture plates
at a seeding density of 5,000 or 10,000 cells/cm2 for osteo-
genic or adipogenic differentiation, respectively. The cellswere induced using osteogenic medium composed of
low-glucose DMEM, 10% FBS, 10 mM β-glycerophosphate,
50 μg/ml L-ascorbic acid-2-phosphate, 0.1 μM dexametha-
sone (Sigma-Aldrich), and antibiotics, or using adipogenic
medium composed of high-glucose DMEM, 10% FBS, 1
μM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine,
1 μg/ml insulin (Sigma-Aldrich), and antibiotics. To induce
hMSCs for chondrogenic differentiation, a previously de-
scribed protocol with modifications was used [42]. Briefly,
250,000 cells were centrifuged in a 15-ml conical tube at
600 g for 5 minutes to form a high-density cell pellet. The
cell pellet was induced using chondrogenic medium
containing high-glucose DMEM, 1% ITS+ (BD Biosciences),
50 μg/ml L-ascorbic acid-2-phosphate, 0.1 μM dexa-
methasone, 40 μg/ml L-proline, 0.9 mM sodium pyru-
vate (Sigma-Aldrich), and antibiotics, supplemented with
10 ng/ml transforming growth factor beta-1 (TGFB1)
(Peprotech). Differentiation medium was changed every 3
days during differentiation induction.
To analyze osteogenic differentiation of hMSCs, cells
were fixed with 60% isopropanol after 21 days of induc-
tion. The cells were stained for Alizarin red (Rowley
Biochemical, Danvers, MA, USA) to evaluate the extent of
mineral deposition. To quantify the level of mineralization,
calcium deposition in culture was extracted using 0.5 M
hydrogen chloride, and then measured using the LiquiColor
kit (Stanbio, Boerne, TX, USA) following the manufac-
turer’s protocol. For analyzing chondrogenic differenti-
ation, after 21 days of induction, chondrogenic cell
pellets were fixed with 4% formaldehyde solution, dehy-
drated using a series of concentrations of ethanol, infil-
trated with xylene, and then embedded in paraffin. For
histology analysis, the embedded cell pellets were cut into
8-μm sections using a microtome, deparaffinized, rehy-
drated, and then stained with Alcian blue (Polysciences,
Warrington, PA, USA) to detect glycosaminoglycan
(GAG). To quantify GAG production, chondrogenic cell
pellets were digested with papain, and analyzed by the
dimethylmethylene blue (DMMB) assay following a previ-
ously published protocol [43]. Briefly, 16 mg DMMB
(Sigma-Aldrich) was dissolved in 1,000 ml water contain-
ing 3.04 g glycine, 1.6 g NaCl and 95 ml acetic acid. After
200 μl DMMB solution was mixed with 20 μl papain-
digested sample solution, the mixture was measured for
the absorbance at the wavelength of 525 nm to determine
the GAG amount, which was then normalized with the
DNA content determined by the PicoGreen assay. To evalu-
ate adipogenic differentiation, hMSCs were fixed with 4%
formaldehyde solution, and then stained with Oil Red O
(Sigma-Aldrich) for lipid droplet formation after 21 days of
induction. After image analysis, the staining of Oil Red O in
culture was dissolved by 2-propanol. The Oil Red O solution
was then analyzed for the absorbance at the wavelength of
656 nm to determine the amount of lipid droplets.
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To extract protein from hMSCs, the cells were lyzed
using RIPA buffer composed of 50 mM Tris–HCl (pH
7.5), 0.25% Na-deoxycholate, 1% Nonidet P-40, 150 mM
NaCl, 1 mM EDTA, and complete protease inhibitor
cocktail (Roche, Indianapolis, IN, USA). After centrifu-
gation at 14,000 rpm for 10 minutes, the supernatant was
collected. Protein concentration was measured using the
BCA Protein Assay kit (Pierce, Rockford, IL, USA). A 40-μg
protein sample was loaded into each lane of a 10% polyacra-
mide gel (Bio-Rad) for electrophoresis, and the separated
proteins were then transferred from the gel onto a polyviny-
lidene fluoride membrane (Bio-Rad). The membrane
was incubated with primary antibodies against AKT,
phospho-AKT (Ser473), and glyceraldehyde 3-phosphate
dehydrogenase (Cell Signaling, Danvers, MA, USA) in a
blocking solution composed of Tris-buffered saline
containing 5% nonfat milk (Bio-Rad) and 0.1% Tween
20 (Sigma-Aldrich) overnight at 4°C. After removing
unbound antibodies, the membrane was incubated with
horseradish peroxidase-linked secondary antibody (Cell
Signaling) in the blocking solution for 1 hour at room
temperature. The immuno-detected protein bands on
the membrane were visualized using the SuperSignal
West Pico Chemiluminescent Substrate (Pierce), and
then documented by the Kodak Image Station 4000R
Pro system (Kodak, Rochester, NY, USA).
Regulation of AKT signaling
To regulate the activation of the AKT signaling pathway,
0.01 or 0.1 μM AKT Inhibitor IV (EMD Millipore) was
used in hMSC culture. Specifically, ET1-treated hMSCs
were cultured with or without AKT Inhibitor IV for two
passages before qRT-PCR analysis or induction for mul-
tilineage differentiation.
Statistical analysis
All quantitative data of assays that analyze three donors’
cells were presented as the mean ± standard deviation, as
the assays were performed with samples in technical
triplicate (n = 3). A Student’s t-test or one-way analysis
of variance with post-hoc Tukey’s test was used for stat-
istical comparison. A P-value <0.05 was considered sta-
tistically significant.
Results
Human aortic endothelial cells secreted endothelin-1 to
regulate human mesenchymal stem cell activities
We first used hMSC/HAEC co-culture to investigate the
effects of paracrine factors on hMSCs (Figure 1A) and
hMSCs without HAEC as control culture. After 3 days
of culture, cell morphologies of control and co-cultured
hMSCs were similar (Figure 1B). The cell number of
hMSCs co-cultured with HAECs was higher than that ofcontrol hMSCs at day 8 (Figure 1C), suggesting that
HAECs are able to increase proliferation of hMSCs. qRT-
PCR analysis of potency- and lineage-related markers
showed that among cells from all three donors, hMSCs
in co-culture expressed higher mRNA levels of lineage-
related transcription factors CBFA1, SOX9, and PPARG2
than control hMSCs, while the expression levels of OCT3/
4 and NANOG were comparable between co-cultured and
control hMSCs (Figure 1D). To investigate whether ET1
secreted by HAECs in co-culture is able to regulate
hMSCs, we first quantified levels of ET1 in hMSC- and
HAEC-conditioned medium. The ET1 level in HAEC-
conditioned medium was 1,537 ± 86 pg/ml whereas
that in hMSC-conditioned medium was not detectable
(Figure 1E, left). Similarly, the mRNA expression level
of ET1 in HAECs was about 147-fold higher than that
in hMSCs (Figure 1E, right). We next used bosentan, a
non-selective endothelin receptor antagonist, to inhibit
ET1 signaling in hMSCs. Considering the possibility that
adding bosentan directly in hMSC/HAEC co-culture may
affect HAECs and subsequently interfere with hMSC
response, we decided to treat hMSCs with bosentan in
HAEC-conditioned medium instead of in Transwell
co-culture. The mRNA expression levels of CBFA1 and
PPARG2 of donor 1 hMSCs cultured with HAEC-
conditioned medium were higher than those of control
hMSCs cultured without conditioned medium, while
the levels of OCT3/4, NANOG, and SOX9 were com-
parable between the two cultures (Figure 1F). Compared
to hMSCs cultured in HAEC-conditioned medium
without bosentan, the cells in conditioned medium
with 10 μM bosentan expressed a decreased level of
NANOG and those cultured with either 1 or 10 μM
bosentan showed downregulated expression of CBFA1
(Figure 1F). Similar to the results of donor 1 cells, do-
nors 2 and 3 hMSCs cultured in conditioned medium
treated with 10 μM bosentan showed consistent result
patterns compared to their control hMSCs. These results
indicate that inhibition of ET1 signaling attenuates the
effects of HAEC-conditioned medium on regulation of
hMSC activities.
Endothelin-1 upregulated potency- and lineage-related
markers in pre-differentiated human mesenchymal stem
cells
To study the effects of ET1 on hMSC activities, we next
treated hMSCs with recombinant ET1 in culture. Cell
numbers at days 2, 4 or 8 were comparable between cul-
ture treated with or without ET1 (Figure 2A), suggesting
that ET1 does not affect proliferation of hMSCs. We fur-
ther analyzed mRNA expression of potency- and lineage-
related markers of hMSCs under the effect of ET1. The
results showed that the mRNA levels of OCT3/4 and
NANOG in donor 1 hMSCs treated with ET1 were higher
Figure 2 Effects of recombinant endothelin-1 (ET1) on regulation of pre-differentiated human mesenchymal stem cells (hMSCs). (A) Proliferation
of hMSCs treated with or without different doses of ET1 was analyzed by quantifying total DNA content. (B) Relative mRNA expression levels of
potency- and lineage-related markers in hMSCs treated with or without different doses of ET1 for two passages were analyzed by quantitative
RT-PCR. *P < 0.05; n = 3. (C) Growth curves of hMSCs treated with or without 0.1 μM ET1 were generated by calculating cumulative population
doublings. (D) Expression of surface antigens of hMSCs treated with or without 0.1 μM ET1 for two passages was assessed by flow cytometry.
Area under black curve: cells labeled with target antibody; area under gray curve: cells labeled with isotype antibody.
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In addition, compared to the cells without ET1 treatment,
hMSCs treated with 0.1 μM ET1 expressed increased
levels of CBFA1 and SOX9 while those treated with 0.01
μM ET1 expressed only increased SOX9. Donor 2 cells
showed that the expression levels of OCT/4, CBFA1 and
SOX9 in culture treated with 0.1 μM ET1 were higher
than those in culture without ET1. The results of donor 3
cells were similar to those of donor 1 cells or those of
donor 2 cells except for the expression level of NANOG.
The expression levels of PPARG2 were comparable among
all cultures regardless of donor source. These findings
suggest that ET1 enhances the potency of hMSCs and
directs the cells toward the osteogenic or chondrogenic
lineage, and the response of hMSCs is not ET1 dose-
dependent. We thus decided to use the concentration
of 0.1 μM to treat cells in the subsequent experiments.
The results of long-term cell growth showed that the
cumulative PDs of hMSCs treated with or without ET1
were comparable (Figure 2C), suggesting that ET1 does
not affect growth of hMSCs in culture. Lastly, the ex-
pression of surface antigens of hMSCs analyzed by flow
cytometry showed that the cell population treated with
ET1 expressed the levels of CD73, CD90 or CD105
comparable with that in the cell population without
ET1 treatment (Figure 2D). These findings demonstrate
that ET1 treatment does not affect expression of hMSC
surface markers.Endothelin-1 enhanced osteogenic and chondrogenic
capacities of pre-differentiated human mesenchymal
stem cells
We next investigated whether the upregulated expression
of CBFA1 and SOX9 in ET1-treated hMSCs were able to
drive enhanced osteogenesis and chondrogenesis upon
differentiation induction. To this end, hMSCs cultured
with or without ET1 for two passages were induced into
osteogenic, chondrogenic, or adipogenic lineage using
lineage-specific differentiation medium without ET1. After
21 days of osteogenesis, the mRNA levels of bone-related
CBFA1, ALP and OC were upregulated in ET1-pretreated
donor 1 hMSCs, compared to those in hMSCs without
ET1 pretreatment (Figure 3A). ET1-pretreated donor 2
cells showed increased levels of OC and ET1-pretreated
donor 3 cells expressed upregulated levels of CBFA1 and
ALP compared to their control hMSCs without ET1
pretreatment (Figure 3A). In addition to increased mRNA
expression of bone-related markers, ET1-pretreated hMSCs
showed greater intensity of Alizarin red staining than those
without ET1 pretreatment (Figure 3B, left) and all three do-
nors’ hMSCs pretreated with ET1 were able to produce
more calcium deposition than their control cells (Figure 3B,
right). The results of qRT-PCR and calcium deposition ana-
lyses indicate that ET1 increases the osteogenic capacity of
pre-differentiated hMSCs. To investigate the effect of ET1
on the chondrogenic capacity of pre-differentiated hMSCs,
the cells pretreated with or without ET1 were made into
Figure 3 Effects of endothelin-1 (ET1) on regulation of lineage-specific differentiation capacity of pre-differentiated human mesenchymal stem cells
(hMSCs). hMSCs pretreated with (pre-ET1+) or without ET1 (pre-ET1-) for two passages were induced for osteogenesis (A,B), chondrogenesis (C,D), or
adipogenesis (E,F) for 21 days. (A,B) Osteogenesis was evaluated by analyzing relative mRNA expression levels of bone-related markers (A) or Alizarin
red staining and quantification of calcium deposition (B). (C,D) Chondrogenesis was assessed by analyzing relative mRNA expression levels of
cartilage-related markers (C) or Alcian blue staining and quantification of glycosaminoglycan (GAG) production (D). (E,F) Adipogenesis was
evaluated by analyzing relative mRNA levels of fat-related markers (E) or Oil Red O staining and quantification of lipid droplets (F). *P < 0.05; n = 3.
Scale bar: 200 μm.
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for 21 days. Cell pellets made of ET1-pretreated donor
1 hMSCs showed higher mRNA levels of cartilage-related
AGN and COL2 than those made of hMSCs without ET1
pretreatment (Figure 3C). Cell pellets made of ET1-
pretreated donor 2 or 3 hMSCs expressed upregulated
mRNA levels of SOX9 and AGN or increased levels of
COL2, respectively, compared to its control cells with-
out ET1 pretreatment (Figure 3C). Histological analysis
showed greater intensity of Alcian blue staining in cell
pellets of ET1-pretreated hMSCs than that in cell pel-
lets of hMSCs without ET1 pretreatment (Figure 3D, left).
Moreover, cell pellets of all three donors’ hMSCs pre-
treated with ET1 produced more GAGs than those of
their control hMSCs without being pretreated with ET1
(Figure 3D, right). These findings suggest that ET1 upregu-
lates the chondrogenic capacity of pre-differentiated hMSCs.
Adipogenic differentiation of ET1-pretreated hMSCs was
also examined. After 21 days of induction, hMSCs from all
three donors showed comparable mRNA levels of PPARG2
and LPL between cultures with or without ET1 pretreat-
ment (Figure 3E). Analysis of lipid droplet productiondetected by Oil Red O showed similar intensity of staining
(Figure 3F, left) and comparable amounts of lipid droplets in
hMSCs pretreated with or without ET1 (Figure 3F, right),
suggesting that ET1 does not affect the adipogenic capacity
of pre-differentiated hMSCs. These results, together with
those shown in Figure 2B, suggest that ET1 primes hMSCs
for osteogenic and chondrogenic differentiation by upregu-
lating the expression of CBFA1 and SOX9.
Endothelin-1 regulated human mesenchymal stem cell
activities through activation of AKT signaling
To test our hypothesis that ET1 regulates hMSC activities
through activation of the AKT signaling pathway, we first
analyzed AKT activation upon ET1 induction in hMSCs.
The results of western blotting showed that AKT in
hMSCs was activated 1, 2, or 4 hours after ET1 induction
(Figure 4A). To attenuate AKT activity, we used AKT In-
hibitor IV in ET1-treated hMSCs. Among the ET1-treated
cells, western blotting analysis showed that the level of
phospho-AKT with 0.01 or 0.1 μM AKT Inhibitor IV
treatment was decreased compared to that without be-
ing treated with AKT inhibitor (Figure 4B). Based on
Figure 4 Response of endothelin-1 (ET1)-treated human mesenchymal stem cells (hMSCs) to regulation of AKT activity. (A) Western blotting
analysis of AKT activation in hMSCs after ET1 induction. (B) Western blotting analysis of AKT activity in hMSCs 2 hours after ET1 induction. The
cells were treated with or without AKT Inhibitor IV before ET1 induction. (C) Relative mRNA expression levels of potency- and lineage-related
markers in ET1-treated hMSCs with or without AKT inhibition for two passages were analyzed by quantitative RT-PCR. (D,E) hMSCs pretreated with
or without ET1 or AKT inhibitor for two passages were induced for 21-day osteogenesis. Osteogenesis was evaluated by analyzing relative mRNA
expression levels of bone-related markers (D) or Alizarin red staining and quantification of calcium deposition (E). (F,G) hMSCs pretreated with
or without ET1 or AKT inhibitor for two passages were made into cell pellets and induced for 21-day chondrogenesis. Chondrogenesis was
assessed by analyzing relative mRNA expression levels of cartilage-related markers (F) or Alcian blue staining and quantification of glycosaminoglycan
(GAG) production (G). *P< 0.05; n = 3. Scale bar: 200 μm.
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to effectively attenuate AKT activity in the subsequent
experiments. We then examined the expression of
potency- and lineage-related markers in ET1-treated
hMSCs with or without AKT inhibition. We found that
the mRNA levels of OCT3/4, NANOG, and SOX9 in
ET1-treated donor 1 hMSCs with AKT inhibitor were
downregulated compared to those without AKT inhibitor,
while the levels of CBFA1 were comparable between the
culture with and without AKT inhibitor (Figure 4C). The
mRNA levels of OCT3/4, CBFA1 and SOX9 in ET1-
treated donor 2 hMSCs and those of OCT3/4, NANOG,
CBFA1 and SOX9 in ET1-treated donor 3 hMSCs treated
with AKT inhibitor were decreased compared to those of
their control cells without being attenuated by AKT in-
hibitor (Figure 4C). Moreover, after being treated with or
without ET1 or AKT Inhibitor IV for two passages, the
cells were then induced for osteogenesis and chondrogen-
esis without ET1 or AKT inhibitor. The results showed
that after 21 days of osteogenic induction, donor 1 hMSCs
pretreated with ET1 and AKT inhibitor expressed lowermRNA levels of ALP and OC than those with ET1 but
without AKT inhibitor (Figure 4D). Donor 2 or 3 hMSCs
pretreated with ET1 and AKT inhibitor expressed lower
levels of OC or CBFA1 and ALP, respectively, than those
of its control cells with ET1 but without AKT inhibitor
(Figure 4D). Analysis of Alizarin red staining showed de-
creased staining intensity in ET1- and AKT inhibitor-
pretreated hMSCs, compared to that in ET1-pretreated
cells (Figure 4E, left). The amount of calcium deposition
produced by ET1- and AKT inhibitor-pretreated hMSCs
was also less than that of ET1-pretreated cells (Figure 4E,
right). For the analysis of chondrogenesis, after 21 days
of induction, cell pellets made of ET1- and AKT inhibitor-
pretreated donor 1 hMSCs expressed lower mRNA levels
of SOX9, AGN and COL2 than those made of ET1-
pretreated hMSCs or control hMSCs without ET1 pre-
treatment (Figure 4F). Cell pellets made of ET1- and AKT
inhibitor-pretreated donor 2 or 3 hMSCs expressed
lower levels of AGN and COL2 than those made of
ET1-pretreated hMSCs (Figure 4F). Moreover, intensity of
Alcian blue staining in cell pellets of ET1- and AKT
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that in cell pellets of ET1-pretreated hMSCs or control
hMSCs (Figure 4G, left). The GAG content in cell pellets
made of ET1- and AKT inhibitor-pretreated hMSCs of all
three donors was also lower than that in cell pellets made
of ET1-pretreated cells (Figure 4G, right). Together these
results showed that ET1 activated AKT signaling in
hMSCs, and inhibiting AKT activity attenuated the effects
of ET1 on upregulation of the osteogenic and chondro-
genic capacities of pre-differentiated hMSCs.
Endothelin-1 increased expression of human mesenchymal
stem cell surface markers and osteogenic capacity of human
embryonic stem cell-derived mesenchymal stem cells
We next examined the effect of ET1 on hESC-MSCs,
another type of hMSC, to determine whether the regula-
tion by ET1 is specific to bone marrow-derived MSCs or
general to a variety of hMSCs regardless of their sources.
The expression of potency- and lineage-related markers
showed that the mRNA level of CBFA1 in hESC-MSCs
treated with ET1 was significantly higher than that in
hESC-MSCs without ET1 treatment, while the levels of
OCT3/4, NANOG, and SOX9 were comparable between
cells treated with and without ET1 (Additional file 1:
Figure S1A), suggesting that ET1 directs hESC-MSCs
toward the osteogenic lineage. Moreover, we found that
after ET1 treatment in the cell population of hESC-MSCs
treated with ET1, the percentages of hESC-MSCs express-
ing CD73, CD90, or CD105 were increased from 91.9%,
57.6%, or 56.7% to 94.8%, 78.8%, or 79.9%, respectively
(Additional file 1: Figure S1B). This finding suggests that
ET1 treatment may select a subpopulation of hESC-MSCs
or prime the cells toward the mesenchymal lineage.
hESC-MSCs treated with ET1 for two passages were then
induced without ET1 for osteogenesis or chondrogenesis.
After 21 days of osteogenesis, the mRNA levels of
bone-related CBFA1 and ALP were upregulated in ET1-
pretreated hESC-MSCs, compared to those in hESC-
MSCs without ET1 pretreatment (Additional file 1:Figure 5 A proposed mechanistic model to illustrate the interaction betwe
(hMSCs). Endothelin-1 (ET1) secreted by ECs is able to activate AKT signalin
osteogenic and chondrogenic capacities.Figure S1C). Analysis of mineral deposition using Alizarin
red staining showed mineralization in ET1-pretreated
hESC-MSC culture, while intensity of the staining was
barely detectable in hESC-MSC culture without ET1
pretreatment (Additional file 1: Figure S1D, left). The
amount of calcium deposition produced by ET1-pretreated
hESC-MSCs was also significantly more than that pro-
duced by control hESC-MSCs without ET1 pretreatment
(Additional file 1: Figure S1D, right). These results indi-
cate that ET1 enhances the osteogenic capacity of pre-
differentiated hESC-MSCs. For the effect of ET1 pre-
treatment on hESC-MSC chondrogenesis, cell pellets made
of hESC-MSCs pretreated with or without ET1 induced
for 21 days expressed comparable mRNA levels of SOX9,
AGN and COL2 (Additional file 1: Figure S1E). Alcian
blue staining showed similar levels of intensity (Additional
file 1: Figure S1F, left) and DMMB analysis indicated com-
parable amounts of GAG production (Additional file 1:
Figure S1F, right) between chondrogenic cell pellets made
of hESC-MSCs pretreated with and without ET1, suggest-
ing that ET1 does not affect the chondrogenic capacity of
pre-differentiated hESC-MSCs.
Discussion
In this study, we demonstrate that co-cultured ECs se-
crete ET1 to upregulate the osteogenic and chondro-
genic capacities of pre-differentiated hMSCs. We further
demonstrate that the effects of ET1 on hMSCs are medi-
ated by AKT signaling. Based on our findings, we propose
a working model describing the mechanism by which ECs
regulate the osteogenic and chondrogenic capacities of
pre-differentiated hMSCs through secreted ET1 activating
AKT signaling (Figure 5).
hMSCs residing in a perivascular niche lie in close
proximity to ECs [11,14]. Our study uses hMSC/HAEC
co-culture, HAEC-conditioned medium, and ET1-treated
culture to investigate activities of bone marrow-derived
hMSCs regulated by ECs and soluble ET1. Specifically, pre-
differentiated hMSCs co-cultured with HAECs or treateden endothelial cells (ECs) and human mesenchymal stem cells
g in hMSCs to upregulate CBFA1 and SOX9, thereby increasing the
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SOX9, indicating that ECs and their secreted ET1 play an
important role in regulation of hMSC osteogenesis and
chondrogenesis. Unlike the hematopoietic stem cell niche
that has been extensively studied, the biological regula-
tion in the hMSC niche remains largely unknown
[44,45]. Our results provide insight into the regulatory
mechanism underlying the interaction between hMSCs
and ECs, which may help gain a better understanding of
hMSC behavior in a perivascular niche.
Our results show that behavior of hMSCs co-cultured
with HAECs is different from that of hMSCs treated
with recombinant ET1. hMSCs treated with recombinant
ET1 express increased levels of OCT3/4 and NANOG
while those co-cultured with HAECs show comparable
expression levels of these two mRNA transcripts, com-
pared to their control cells. In addition, the proliferation
results indicate that co-cultured HAECs enhance hMSC
propagation but ET1 does not affect proliferation of
hMSCs. The discrepancy between hMSC activities reg-
ulated by ET1 and co-cultured HAECs suggests that
ET1 is not the only soluble factor secreted by HAECs
contributing to the results of hMSC regulation demon-
strated in this study. Other molecules, such as platelet-
derived growth factor, fibroblast growth factor, Wnt,
bone morphogenetic protein, and Notch, have also been
reported to be involved in the regulation of hMSC ac-
tivities by ECs [18,19,46]. Further, our results also show
that the expression of SOX9 is enhanced in hMSCs co-
cultured with HAECs but not in the cells cultured with
HAEC-conditioned medium. This is probably due to
different extents of ET1 stimulation associated with our
culture setup: hMSCs with co-cultured HAEC were stim-
ulated by continually released ET1 whereas those with
HAEC-conditioned medium only by a single dose of ET1.
Nevertheless, we believe that our results analyzed based
on three donors’ cells collectively suggest that ET1 pre-
treatment can enhance the osteogenic and chondrogenic
capacities of pre-differentiated hMSCs.
In this study, we investigate the effect of ET1 on hMSCs
prior to differentiation and demonstrate a new finding
that ET1 enhances the osteogenic capacity of pre-
differentiated hMSCs through upregulation of CBFA1.
Previous studies have also demonstrated that ET1 is
able to enhance osteogenesis [22-24], but unlike our
experimental setup focusing on the pre-differentiation
stage, they study the effect of ET1 on osteogenesis dur-
ing differentiation induction. These findings together
may suggest that ET1 is able to regulate osteogenesis
of hMSCs either prior to or during osteogenic induc-
tion through different mechanisms. In addition, our re-
sults show that ET1 does not affect proliferation of
hMSCs, which is not in agreement with the previous
finding suggesting that ET1 promotes proliferation ofhMSCs [25]. The discrepancy between their and our
findings in cell proliferation regulated by ET1 may be
attributed to the difference in hMSC property. hMSCs
used in our study are isolated from bone marrow whereas
the cells used in their study are harvested from lung. It is
possible that bone marrow- and lung-derived hMSCs have
different biological properties that may prompt different
degrees of cell proliferation in response to ET1 stimula-
tion. While seeming to be rational, this hypothesis needs
to be tested by a further study.
Our results show that ET1 induces activation of AKT
signaling in pre-differentiated hMSCs to upregulate their
osteogenic and chondrogenic capacities. Specifically, we
demonstrate that activation of AKT signaling by ET1
upregulates expression of CBFA1 and SOX9 in hMSCs,
which primes the cells for osteogenic and chondrogenic
induction. Previous studies have shown that the AKT
signaling pathway is associated with the regulation of
CBFA1 or SOX9 in other cell types. For example, Ling
and colleagues have reported that activation of AKT
signaling upregulates the expression of CBFA1 to en-
hance osteogenesis of MC3T3-E1 pre-osteoblast cells
[47]. The study by Cheng and colleagues or Ikegami and
colleagues has shown that the expression of SOX9 is regu-
lated by the AKT signaling pathway in nucleus pulposus
cells [48] or chondrocytes [49], respectively. In this study,
we demonstrate that attenuation of AKT signaling in pre-
differentiated hMSCs inhibits chondrogenic differenti-
ation. A previous report by Li and colleagues has shown
that TGFB induces activation of AKT in precartilaginous
stem cells, and inhibition of AKT activity suppresses
TGFB-induced expression of SOX9, AGN, and COL2
[50], indicating the crucial role of AKT signaling in chon-
drogenesis. In addition to the AKT signaling pathway, other
pathways, such as the mitogen activated-protein kinase
pathway [26,27] or the Ca2+/calmodulin-dependent protein
kinase cascade [28], activated by ET1, may also be involved
in the regulation of hMSC activities induced by ECs. How-
ever, investigation into how ECs regulate hMSCs through
other signaling pathways is beyond the scope of this study.
We plan to carry out the investigation in future studies.
hMSCs isolated or derived from adult tissue and embry-
onic sources are likely to have different cell properties and
behavior [51]. For example, studies have shown that com-
pared to human bone marrow-derived MSCs, hMSCs de-
rived from hESCs are less inducible for mesenchymal
lineage-specific differentiation [52,53]. Our results demon-
strate that ET1 is able to increase the osteogenic capacity
of hESC-MSCs by upregulating the expression of CBFA1,
suggesting that ET1 primes pre-differentiated hESC-MSCs
for subsequent osteogenic induction. Considering our
finding that both human bone marrow- and ESC-derived
MSCs are primed by ET1 for osteogenic induction, we
hereby hypothesize that the effect of ET1 on priming the
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cells derived from different sources. On the other hand,
ET1 does not enhance the expression of SOX9 in pre-
differentiated hESC-MSCs nor chondrogenesis as it does
in bone marrow-derived hMSCs, suggesting that the effect
of ET1 on regulation of pre-differentiated hESC-MSCs for
chondrogenesis and for osteogenesis may be different.
Interestingly, our flow cytometry results seem to suggest
that hESC-MSCs are composed of heterogeneous cell
populations [53,54]. We demonstrate that ET1 increases
the percentage of the cells expressing hMSC-related
surface markers in a hESC-MSC population. In addition
to our findings, previous studies have shown that ET1 is
able to promote epithelial-to-mesenchymal [55,56] or
endothelial-to-mesenchymal transition [57] in various
cell types through the ET1/endothelin receptor type A
signaling pathway. Taken together, our study demon-
strates that ET1 plays an important role not only in
regulation of biological response of adult tissue-derived
MSCs but also in directing hESCs into MSC-like cells.Conclusions
It will enhance our knowledge of how hMSCs behave and
function in a perivascular niche if we better understand the
interaction between hMSCs and ECs. The knowledge is im-
portant to developing potential applications in tissue engineer-
ing and regenerative medicine. Our results demonstrate that
ECs can secrete ET1 to regulate pre-differentiated hMSCs for
subsequent induction of osteogenic and chondrogenic differ-
entiation, and the regulation is mediated through the AKTsig-
naling pathway. Our findings provide insight into one of the
mechanisms governing how ECs regulate hMSC activities.Note: This article is part of an ‘Emerging Investigators’ collection
showcasing the work of early career investigators who have
demonstrated growing leadership in the field of stem cells and
regenerative medicine. Other articles in the series can be found
online at http://stemcellres.com/series/emerginginvestigators.Additional file
Additional file 1: Figure S1. Effects of ET1 on regulation of hESC-MSC
activities. (A) Relative mRNA expression levels of potency- and lineage-
related markers in hESC-MSCs treated with or without 0.1 μM ET1 for two
passages were analyzed by qRT-PCR. (B) Expression of surface antigens of
hESC-MSCs treated with or without 0.1 μM ET1 for two passages was assessed
by flow cytometry. Area under black curve: cells labeled with target antibody;
area under gray curve: cells labeled with isotype antibody. (C,D) hESC-MSCs
pretreated with or without ET1 were induced for 21-day osteogenesis.
Osteogenesis was assessed by analyzing relative mRNA expression levels of
bone-related markers (C) or Alizarin red staining and quantification ofcalcium deposition (D). Scale bar: 200 μm. (E,F) Pellets made of hESC-MSCs
pretreated with or without ET1 were induced for 21-day chondrogenesis.
Chondrogenesis was evaluated by relative mRNA expression levels of
cartilage-related markers (E) or Alcian blue staining and quantification
of GAG production (F). Scale bar: 100 μm. *P < 0.05; n = 3.
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